Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 235-935-5 | CAS number: 13052-09-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Justification for selection of genetic toxicity endpoint
Ames + MLA + in vivo micronucleus, K1: The study was performed according to OECD guidelines and GLP.
Short description of key information:
The substance is positive for mutagenicity with metabolic activation in vitro in an Ames test and negative in a Mouse Lymphoma Assay.
In accordance with Endpoint Specific Guidance Chapter R.7A, Figure R.7.7-1 "Flow chart of the mutagenicity testing strategy", no further testing (i.e. no in vivo testing) need be proposed in the event of a negative mouse lymphoma assay or hprt assay, regardless to whether or not the gene mutation test in bacteria is positive or negative. This therefore implies that when considering whether an in vivo gene mutation request is required for substances requiring Annex IX test proposals due to their volume bands, a negative mouse lymphoma assay or hprt assay is sufficient evidence to waive the need for an in vivo gene mutation test.
There is no in vitro cytogenicity study available however an in vivo micronucleus study is negative.
Endpoint Conclusion:No adverse effect observed (negative)
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 23 December 1999 - 10 March 1999
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study is performed according to OECD guidelines and GLP.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- Histidine operon
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Additional strain / cell type characteristics:
- other: see below
- Species / strain / cell type:
- S. typhimurium TA 102
- Additional strain / cell type characteristics:
- other: see below
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9-mix
- Test concentrations with justification for top dose:
- preliminary tes, with and withou S9-mixt: 10, 100, 500, 1000, 2500 and 5000 µg/plate.
Experiments without S9 mix:
The selected treatment-levels were:
312.5, 625, 1250, 2500 and 5000 µg/plate, for all tester strains in both mutagenicity experiments, except for the TA 98 strain in the second experiment, 625, 1250, 2500, 3750 and 5000 µg/plate, for the TA 98 strain in the second experiment.
Experiments with S9 mix:
The selected treatment-levels were:
312.5, 625, 1250, 2500 and 5000 µg/plate, for all tester strains In both mutagenicity experiments. - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Justification for choice of solvent/vehicle: solubility
Batch No. 1743850 731 (Merck Clevenot, 77500 Chelles, France). - Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: see below
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: preincubation
DURATION
- Preincubation period: 60 min.
- Exposure duration: 48/72 hours
- Expression time (cells in growth medium): 48/72 hours
SELECTION AGENT (mutation assays): histidine
NUMBER OF REPLICATIONS: triplicate
NUMBER OF CELLS EVALUATED: revertants were scored with an automatic counter (Anek counter, model 880, OS1, 750] 5 Paris, France).
DETERMINATION OF CYTOTOXICITY: The evaluatiDn of the tDxicity was perfonned Dn the basis of the observation Df the decrease in the number of revertant cDlonies andlDr a thinning of the bacterial lawn. - Evaluation criteria:
- Acceptance criteria
This study would be considered valid since the following criteria are fully met:
· the number of revertants in the vehicle controls is consistent with our historical data,
· the number of revertants in the positive controls is higher than that of the vehicle controls and is consistent with our historical data.
Evaluation criteria
A reproducible two-fold increase in the number of revertants compared with the vehicle controls, in any strain at any dose-level and/or evidence of a dose-relationship was considered as a positive result. Reference to historical data, or other considerations of biological relevance may also be taken into account in the evaluation of the data obtained. - Statistics:
- None
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- with
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 1537
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 102
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- RANGE-FINDING/SCREENING STUDIES:
The test substance was soluble in the vehicle (DMSO) at 50 mg/ml. With a maximum dose volume of 100 µg/plate. No precipitate was observed in the Petri plates when scoring the revertants at all dose-levels. No toxicity was noted towards the three strains used, with and without S9 mix. - Conclusions:
- Interpretation of results (migrated information):
positive with metabolic activation
Under our experimental conditions, the test substance induced mutagenic activity in the bacterial reverse mutation test on TA 98 and TA 100 Salmonella typhimurium strains, with metabolic activation. - Executive summary:
A preliminary toxicity test was performed to define the dose-levels to be used for the mutagenicity study. The test substance was then tested in two independent experiments, with and without a metabolic activation system, the S9 mix, prepared from a liver microsomal fraction (S9 fraction) of rats induced with Aroclor 1254. Both experiments were performed according to the direct plate incorporation method except the second with S9 mix, which was performed according to the preincubation method (60 minutes, 37C).
Five strains of bacteria Salmonella typhimurium: TA 1535, TA 1537, TA 98, TA 100 and TA102 were used. Each strain was exposed to five dose-levels of the test substance (three plates/dose-level).
After 48 to 72 hours of incubation at 37C, the revertant colonies were scored.
The evaluation of the toxicity was performed on the basis of the observation of the decrease in the number of revertant colonies and/or a thinning of the bacterial lawn. The test substance was dissolved in dimethylsulfoxide (DMSO).
The test substance was soluble in the vehicle at 50 mg/ml. Consequently, with a maximum dose volume of 100 µg/plate, the dose-levels for the preliminary toxicity test were: 10, 100, 500, 1000, 2500 and 5000 µg/plate. Since the test substance was non-toxic in the preliminary test, the highest dose-level was 5000 µg/plate, according to the criteria specified in the international guidelines.
Experiments without S9 mix:
The selected treatment-levels were:
312.5. 625, 1250. 2500 and 5000 µg/plate for all tester strains in both mutagenicity experiments except for the TA 98 strain in the second experiment. 625, 1250.2500, 3750 and 5000 µg/plate for the TA 98 strain in the second experiment. A slight to moderate emulsion was hoted in the plates at dose levels ≥ 1250 µg/plate. No or a slight toxicity was noted depending on the tester strain and the dose-level. No mutagenic effect was noted in all the tester strains.
Experiments with S9 mix:
The selected treatment-levels were:
312.5. 625. 1250. 2500 and 5000 µg/plate for all tester strains in both mutagenicity experiments.
A slight to moderate emulsion was generally noted in the plates at dose-levels ≥1250 µg/plate. No or a slight to moderate toxicity was noted. depending on the tester strain, the dose-levels and experimental conditions.
In the second experiment (preincubation method), at dose-levels ≥ 625 µg/plate, a 1.8-2.4 fold and a 2-3.7 fold increase in the number of revertants were noted in the TA 98 and TA 100 strain, respectively.
The number of revertants of the vehicle and positive controls was as specified in the acceptance criteria. The study was therefore considered valid.
Under our experimental conditions, the test substance induced mutagenic activity in the bacterial reverse mutation test on TA 98 and TA 100
Salmonella typhimurium strains, with metabolic activation.
- Endpoint:
- in vitro cytogenicity / micronucleus study
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- an in vitro cytogenicity study in mammalian cells or in vitro micronucleus study does not need to be conducted because adequate data from an in vivo cytogenicity test are available
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 05 September 2011 and 24 October 2011
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- According to OECD 476. Study conducted in compliance with agreed protocols, with no or minor deviations from standard test guidelines and/or minor methodological deficiencies, which do not affect the quality of the relevant results. The study report was conclusive, done to a valid guideline and the study was conducted under GLP conditions.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.17 (Mutagenicity - In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- no
- Principles of method if other than guideline:
- first experiment: 4 hours treatment with and without metabolic activation
second experiment: 24 hours treatment without metabolic activation, 4 hours treatment with metaoblic activation - GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- mammalian cell gene mutation assay
- Target gene:
- Thymidine Kinase Locus
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- - Type and identity of media: RPMI
- Periodically checked for Mycoplasma contamination: yes
- Periodically checked for karyotype stability: yes
- Periodically "cleansed" against high spontaneous background: yes - Additional strain / cell type characteristics:
- other: Clone 3.7.2C
- Metabolic activation:
- with and without
- Metabolic activation system:
- Phenobarbital/Beta-Naphtoflavone induced Rat liver S9
- Test concentrations with justification for top dose:
- Experiment I:
without S9 mix (4 hours treatment): 8.8; 17.5; 35.0; 70.0; 140.0; 210.0; and 280.0 µg/mL
with S9 mix (4 hours treatment): 70.0; 140.0; 280.0; 560.0; 840.0; and 1120.0 µg/mL
Experiment II:
without S9 mix (24 hours treatment): 2.2; 4.4; 8.8; 17.5; 35.0; 52.5; and 70.0 µg/mL
with S9 mix (4 hours treatment): 35.0; 70.0; 140.0; 280.0; 560.0; and 840.0 µg/mL
On the day of the experiment (immediately before treatment), the test item was dissolved in acetone. The solvent was chosen according to its solubility properties and its relative nontoxicity to the cells. The final concentration of acetone in the culture medium was 0.5 % v/v. The complete dilution series in acetone was kept on ice until application to the cell cultures. - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: acetone
- Justification for choice of solvent/vehicle: solubility properties - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- methylmethanesulfonate
- Remarks:
- without metabolic activation
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- Remarks:
- with metabolic activation
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration: 4 hours with and without metabolic activation in experiment 1, 24 hours without metaoblic activation in experiment and 4 hours with metabolic activation in experiment 2
- Expression time (cells in growth medium): 48 hours
- Selection time (if incubation with a selection agent): 10 to 15 days
SELECTION AGENT (mutation assays): RPMI 1640 medium by addition of 5 µg/mL TFT
NUMBER OF REPLICATIONS: 2
NUMBER OF CELLS EVALUATED: >1,5 x 10 exp. 6 cells
DETERMINATION OF CYTOTOXICITY
- Method: relative total growth
- Evaluation criteria:
- A test item is classified as mutagenic if the induced mutation frequency reproducibly exceeds a threshold of 126 colonies per 10 exp. 6 cells above the
corresponding solvent control or negative control, respectively.
A relevant increase of the mutation frequency should be dose-dependent.
A mutagenic response is considered to be reproducible if it occurs in both parallel cultures.
However, in the evaluation of the test results the historical variability of the mutation rates in negative
and/or vehicle con¬trols and the mutation rates of all negative and/or vehicle controls of this study are taken into consideration.
Results of test groups are generally rejected if the relative total growth, and the cloning efficiency 1 is less than 10 % of the vehicle control
unless the exception criteria specified by the IWGT recommendations are fulfilled.
Whenever a test item is considered mutagenic according to the above mentioned criteria, the ratio of small versus large colonies is used
to differentiate point mutations from clastogenic effects. If the increase of the mutation frequency is accompanied by a reproducible and
dose dependent shift in the ratio of small versus large colonies clastogenic effects are indicated. - Statistics:
- Linear regression analysis (least squares) using SYSTAT 11 (SYSTAT Software, Inc., 501, Canal Boulevard, Suite C, Richmond, CA 94804, USA)
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: pH 7.33 measured in the solvent control and at concentrations of 4500 µg/mL and 2250 µg/mL of test item
- Effects of osmolality: mOsm of 348 measured in the solvent control versus 295 at 4500 µg/mL and 325 at 2250 µg/mL
- Evaporation from medium: not examined
- Water solubility: Not indicated
- Precipitation:
Pre-experiment :
The test medium was checked for precipitation or phase separation at the end of the treatment period (4 hours) before the test item was removed. Phase separation was noted at 562.5 µg/mL and above with and without metabolic activation following 4 hours treatment. Following 24 hours treatment, phase separation occurred at 140.6 µg/mL and above.
Main experiments:
The culture medium was checked for precipitation or phase separation at the end of treatment. Phase separation was noted in the first experiment at 280 µg/mL and above with and at 280 µg/mL without metabolic activation. In the second experiment phase separation was observed at 560 µg/mL and above with metabolic activation.
- Other confounding effects: None
RANGE-FINDING/SCREENING STUDIES:
The highest concentration should be 10 mM, but not higher than 5 mg/mL or 5 µL/mL, unless limited by the solubility or toxicity of the test item.
RSG (Relative Suspension Growth) or RTG (Relative Total Growth) values (main experiment) below 50% are considered toxic. In case of toxic effects, the highest test item concentration of the main experiment should reduce the RSG or RTG value to approximately 10 - 20%.
The pre-experiment was performed in the presence (4 h treatment) and absence (4 h and 24 h treatment) of metabolic activation. Test item concentrations between 35.2 µg/mL and 4500 µg/mL (equal to a molar concentration of approximately 10 mM) were used. The highest concentration in the pre-experiment was chosen with regard to the purity (95.59%, preliminary information at the start of the experiment) and the molecular weight (430.618 g/mol) of the test item.
Toxic effects leading to RSG values below 50% were observed at 35.2 µg/mL and above in the absence and at 562.5 µg/mL and above in the presence of metabolic activation (4 hours treatment). After 24 hours treatment relevant toxic effects as described above occurred at 35.2 µg/mL and above.
The test medium was checked for precipitation or phase separation at the end of the treatment period (4 hours) before the test item was removed. Phase separation was noted at 562.5 µg/mL and above with and without metabolic activation following 4 hours treatment. Following 24 hours treatment, phase separation occurred at 140.6 µg/mL and above.
Both, pH value and osmolarity were determined in the pre-experiment at the two highest concentrations of the test item and in the solvent control without metabolic activation. There was no relevant shift of both parameters.
The dose range of the first and second experiment was set according to the cytotoxicity and solubility data generated in the pre-experiment. In both main experiments the individual concentrations were generally spaced by a factor of 2.0. A narrower spacing was used at the highest concentrations to cover the cytotoxic or phase separating range more closely.
To overcome problems with possible deviations in toxicity and solubility the main experiments were started with more than four concentrations.
COMPARISON WITH HISTORICAL CONTROL DATA: Complies
ADDITIONAL INFORMATION ON CYTOTOXICITY:
Relevant toxic effects indicated by a relative total growth of less than 50% were observed at 70 µg/mL and above in the first experiment without metabolic activation in culture II or at 140 µg/mL and above in culture II. In the second experiment without metabolic activation cytotoxic effects as described were noted at 17.5 µg/mL and above in culture I and at 35.0 µg/mL and above in culture II. In the second experiment with metabolic activation cytotoxicity occurred at 560 µg/mL and above with metabolic activation (culture I). The recommended cytotoxic range of approximately 10-20% relative total growth was covered in the second experiment without metabolic activation. In the presence of metabolic activation or after 4 hours treatment in the absence of metabolic activation, the dose range was limited by the solubility of the test item (phase separation). - Remarks on result:
- other: strain/cell type: in vitro gene mutation assay with L5178Y cells
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results (migrated information):
negative
Under the experimental conditions reported the test item did not induce mutations in the mouse lymphoma thymidine kinase locus assay using the cell line L5178Y in the absence and presence of metabolic activation. - Executive summary:
The study was performed to investigate the potential of 1,1,4,4- tetramethylbutane- 1,4- diyl bis(2- ethylperoxyhexanoate) (CAS 13052- 09- 0) to induce mutations at the mouse lymphoma thymidine kinase locus using the cell line L5178Y.
The assay was performed in two independent experiments, using two parallel cultures each. The first main experiment was performed with and without liver microsomal activation and a treatment period of 4 hours. The second experiment was performed in the absence of metabolic activation with a treatment period of 24 hours in the absence and 4 hours in the presence of metabolic activation.
The main experiments were evaluated at the following concentrations with and without metabolic activation:
Experiment I
without S9 mix: 35.0; 70.0; 140.0; 210.0; and 280.0 µg/mL
with S9 mix: 140.0; 280.0; 560.0; 840.0; and 1120.0 µg/mLExperiment II
without S9 mix: 4.4; 8.8; 17.5; 35.0; and 52.5 µg/mL
with S9 mix: 70.0; 140.0; 280.0; 560.0; 840.0 µg/mLRelevant toxic effects indicated by a relative total growth of less than 50% were observed at 70 µg/mL and above in the first experiment without metabolic activation in culture II or at 140 µg/mL and above in culture II. In the second experiment without metabolic activation cytotoxic effects as described were noted at 17.5 µg/mL and above in culture I and at 35.0 µg/mL and above in culture II. In the second experiment with metabolic activation cytotoxicity occurred at 560 µg/mL and above with metabolic activation (culture I). The recommended cytotoxic range of approximately 10- 20% relative total growth was covered in the second experiment without metabolic activation. In the presence of metabolic activation or after 4 hours treatment in the absence of metabolic activation, the dose range was limited by the solubility of the test item (phase separation).
The culture medium was checked for precipitation or phase separation at the end of treatment. Phase separation was noted in the first experiment at 280 µg/mL and above with and at 280 µg/mL without metabolic activation. In the second experiment phase separation was observed at 560 µg/mL and above with metabolic activation.
No substantial and reproducible dose dependent increase of the mutation frequency was observed in both experiments.
In the first culture of the second experiment without metabolic activation an isolated increase of the mutation frequency exceeding the threshold of 126 above the corresponding solvent control occurred at an intermediate concentration of 17.5 µg/mL. This isolated increase was judged as irrelevant since no comparable increase was noted in the parallel culture under identical conditions or at higher concentrations in both parallel cultures. Furthermore, the increase was not dose dependent as indicated by the lacking statistical significance.
A linear regression analysis (least squares) was performed to assess a possible dose dependent increase of mutant frequencies using SYSTATâ11statistics software. A significant dose dependent trend of the mutation frequency indicated by a probability value of <0.05 was determined in the second culture of the second experiment without metabolic activation.This trend however, was judged as irrelevant since it actually was reciprocal, going down versus increasing concentrations. Another significantincrease was calculated in culture II of the second experiment in the presence of metabolic activation. This trend however, is considered a biologically irrelevant fluctuation since the mutation frequency did not exceed the threshold of 126 above the corresponding solvent control and it is not reproduced in the parallel culture.
In this study the range of the solvent controls was from 85 up to 115 mutant colonies per 106cells; the range of the groups treated with the test item was from 66 up to 222 mutant colonies per 106cells. The viability of the solvent control of the second culture of the first experiment with metabolic activation (63%) fell just short of the lower limit of 65%. This deviation was judged as irrelevant since it was very minor and the viability of the parallel culture remained well within the recommended range.
MMS (19.5 µg/mL in experiment I and 13.0 µg/mL in experiment II) and CPA (3.0 and 4.5 µg/mL) were used as positive controls and showed a distinct increase in induced total mutant colonies and an increase of the relative quantity of small versus large induced colonies with at least one of the concentrations.
Referenceopen allclose all
In the second experiment (preincubation method), at dose-levels ≥ 625 µg/plate, a 1.8-2.4 fold and a 2-3.7 fold increase in the number of revertants were noted in the TA 98 and TA 100 strain, respectively.
Summary Table
relative | mutant | relative | mutant | |||||
conc. µg | S9 | total | colonies/ | total | colonies/ | |||
per mL | mix | growth | 106cells | threshold | growth | 106cells | threshold | |
Column | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
Experiment I / 4 h treatment | culture I | culture II | ||||||
Solv. control with acetone | - | 100.0 | 89 | 215 | 100.0 | 115 | 241 | |
Pos. control with MMS | 19.5 | - | 32.1 | 525 | 215 | 24.9 | 568 | 241 |
Test item | 8.8 | - | culture was not continued# | culture was not continued# | ||||
Test item | 17.5 | - | culture was not continued# | culture was not continued# | ||||
Test item | 35.0 | - | 71.3 | 98 | 215 | 64.8 | 113 | 241 |
Test item | 70.0 | - | 57.7 | 66 | 215 | 35.1 | 149 | 241 |
Test item | 140.0 | - | 34.0 | 92 | 215 | 38.5 | 163 | 241 |
Test item | 210.0 | - | 45.3 | 85 | 215 | 35.3 | 100 | 241 |
Test item | 280 (PS) | - | 34.6 | 139 | 215 | 26.2 | 135 | 241 |
Solv. control with acetone | + | 100.0 | 88 | 214 | 100.0 | 104 | 230 | |
Pos. control with CPA | 3.0 | + | 77.2 | 225 | 214 | 55.5 | 268 | 230 |
Pos. control with CPA | 4.5 | + | 49.8 | 286 | 214 | 41.8 | 504 | 230 |
Test item | 70.0 | + | culture was not continued# | culture was not continued# | ||||
Test item | 140.0 | + | 106.5 | 112 | 214 | 89.3 | 169 | 230 |
Test item | 280 (PS) | + | 115.8 | 73 | 214 | 136.8 | 122 | 230 |
Test item | 560 (PS) | + | 102.1 | 140 | 214 | 86.2 | 141 | 230 |
Test item | 840 (PS) | + | 68.9 | 118 | 214 | 73.1 | 113 | 230 |
Test item | 1120 (PS) | + | 74.6 | 84 | 214 | 61.6 | 112 | 230 |
Experiment II / 24 h treatment | culture I | culture II | ||||||
Solv. control with acetone | - | 100.0 | 92 | 218 | 100.0 | 107 | 233 | |
Pos. control with MMS | 13.0 | - | 28.5 | 442 | 218 | 38.7 | 361 | 233 |
Test item | 2.2 | - | culture was not continued# | culture was not continued# | ||||
Test item | 4.4 | - | 66.8 | 119 | 218 | 95.9 | 101 | 233 |
Test item | 8.8 | - | 53.1 | 130 | 218 | 122.6 | 113 | 233 |
Test item | 17.5 | - | 24.6 | 222 | 218 | 103.4 | 112 | 233 |
Test item | 35.0 | - | 22.1 | 187 | 218 | 29.0 | 92 | 233 |
Test item | 52.5 | - | 5.0 | 136 | 218 | 5.0 | 78 | 233 |
Test item | 70.0 | - | culture was not continued## | culture was not continued## | ||||
Experiment II / 4 h treatment | culture I | culture II | ||||||
Solv. control with acetone | + | 100.0 | 85 | 211 | 100.0 | 85 | 211 | |
Pos. control with CPA | 3.0 | + | 43.9 | 429 | 211 | 67.0 | 257 | 211 |
Pos. control with CPA | 4.5 | + | 23.5 | 538 | 211 | 66.4 | 437 | 211 |
Test item | 35.0 | + | culture was not continued# | culture was not continued# | ||||
Test item | 70.0 | + | 67.4 | 173 | 211 | 142.1 | 93 | 211 |
Test item | 140.0 | + | 52.4 | 164 | 211 | 89.5 | 92 | 211 |
Test item | 280.0 | + | 54.5 | 151 | 211 | 87.3 | 91 | 211 |
Test item | 560 (PS) | + | 46.1 | 126 | 211 | 89.2 | 102 | 211 |
Test item | 840 (PS) | + | 45.1 | 160 | 211 | 59.5 | 102 | 211 |
threshold = number of mutant colonies per 106cells of each solvent control plus 126
# culture was not continued since a minimum of only four analysable concentrations is required
## culture was not continued due to exceedingly severe cytotoxic effects
PS phase separation
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Description of key information
Justification for selection of genetic toxicity endpoint
Ames + MLA + in vivo micronucleus, K1: The study was performed according to OECD guidelines and GLP.
Short description of key information:
The substance is positive for mutagenicity with metabolic activation in vitro in an Ames test and negative in a Mouse Lymphoma Assay.
In accordance with Endpoint Specific Guidance Chapter R.7A, Figure R.7.7-1 "Flow chart of the mutagenicity testing strategy", no further testing (i.e. no in vivo testing) need be proposed in the event of a negative mouse lymphoma assay or hprt assay, regardless to whether or not the gene mutation test in bacteria is positive or negative. This therefore implies that when considering whether an in vivo gene mutation request is required for substances requiring Annex IX test proposals due to their volume bands, a negative mouse lymphoma assay or hprt assay is sufficient evidence to waive the need for an in vivo gene mutation test.
There is no in vitro cytogenicity study available however an in vivo micronucleus study is negative.
Endpoint Conclusion:No adverse effect observed (negative)
Link to relevant study records
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 14 January 2003 - 23 February 2003
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study is performed according to OECD guidelines and GLP.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- micronucleus assay
- Species:
- mouse
- Strain:
- Swiss
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, l'Arbresle, France
- Age at study initiation: on the day of treatment, the animals were approximately 6 weeks old.
- Weight at study initiation: no data
- Assigned to test groups randomly: yes, under following basis: by sex
- Fasting period before study: no
- Housing: by groups in polycarbonate cages
- Diet (e.g. ad libitum): ad libitum, A04 C pelleted maintenance diet (SAFE, Villemoisson-sur-Orge, France).
- Water (e.g. ad libitum): ad libitum
- Acclimation period: at least 5 days before the day of treatment
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2
- Humidity (%): 30-70
- Air changes (per hr): 12
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: 14 January 2003 - 23 February 2003 - Route of administration:
- intraperitoneal
- Vehicle:
- The vehicle was corn oil, batch Nos. 81K2204 and 062k0006 (Sigma, Saint-Quentin-Fallavier, France).
- Details on exposure:
- Route for the vehicle and the test substance: at the request of the Sponsor, the intraperitoneal route was used,
• Volume: 10 mL/kg,
• CPA: oral route, one treatment - Frequency of treatment:
- Two treatments separated by 24 hours
- Post exposure period:
- 24 hours
- Remarks:
- Doses / Concentrations:
500, 1000, 2000 mg/kg bw/day
Basis:
nominal conc. - No. of animals per sex per dose:
- 5 except for the high dose group where 8 animals were used
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- Cyclophosphamide (CPA)
- Justification for choice of positive control(s): guideline recommendation
- Route of administration: Oral
- Doses / concentrations: Batch No. OD203A (Laboratoire Asta Médica, Mérignac, France) dissolved in distilled water at a concentration of 5 mg/mL. The preparation was stored at -20°C and thawed immediately before use. - Tissues and cell types examined:
- bone marrow
- Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION: In order to select the top dose-level for the cytogenetic study, 2000 mg/kg/day were administered twice, to three males and three females. The interval between each administration was 24 hours. Except for piloerection noted in both males and females, no clinical signs were noted. The top dose-level for the cytogenetic test was selected according to the criteria specified in the international guidelines; since no severe toxic effects were observed, the top dose-level was 2000 mg/kg/day. The two other selected dose-levels for the main test were 500 and 1000 mg/kg/day.
TREATMENT AND SAMPLING TIMES ( in addition to information in specific fields): 24 after the last treatment bone marrow samples were taken
DETAILS OF SLIDE PREPARATION: At the time of sacrifice, all the animals were killed by CO2 inhalation in excess. The femurs of the animals were removed and the bone marrow was flushed out using fetal calf serum. After centrifugation, the supernatant was removed and the cells in the sediment were resuspended by shaking. A drop of this cell suspension was placed and spread on a slide. The slides were air-dried and stained with Giemsa. The slides were coded so that the scorer is unaware of the treatment group of the slide under evaluation ("blind" scoring).
METHOD OF ANALYSIS: For each animal, the number of the micronucleated polychromatic erythrocytes (MPE) was counted in 2000 polychromatic erythrocytes; the polychromatic (PE) and normochromatic (NE) erythrocyte ratio was established by scoring a total of 1000 erythrocytes (PE + NE). The analysis of the slides was performed at Microptic, cytogenetic services (2 Langland Close Mumbles, Swansea SA3 4LY, UK), in compliance with GLP, and the Principal Investigator was Natalie Danford. - Evaluation criteria:
- For a result to be considered positive, a statistically significant increase in the frequency of MPE must be demonstrated when compared to the concurrent vehicle control group. Reference to historical data, or other considerations of biological relevance was also taken into account in the evaluation of data obtained.
- Statistics:
- When there was no significant within-group heterogeneity, using the heterogeneity chi-square test value (Lovell et al., 1989) (d), the frequencies of MPE in each treated group was compared with those in the concurrent vehicle control groups by using a 2 x 2 contingency table to
determine the χ2 value (Lovell et al., 1989) (d). When there was significant within-group heterogeneity, then that group was compared with the
control group using a non-parametric analysis, the Mann-Whitney test (Schwartz, 1969) (e). The student "t" test was used for the PE/NE ratio comparison. Probability values of p ≤ 0.05 was considered as significant. - Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- yes
- Vehicle controls validity:
- valid
- Negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- No clinical signs and no mortality were observed in the animals of both sexes given 500 and 1000 mg/kg/day. Piloerection was noted in both males and females at 2000 mg/kg/day.
For both males and females, the mean values of MPE in the groups treated with the test item, were equivalent to those of the vehicle control group.
The PE/NE ratio was significantly (p < 0.001) lower when compared to that of the vehicle control group, in the males treated at 2000 mg/kg/day, showing that the bone marrow cells were effectively exposed to the test item.
Cyclophosphamide induced a highly significant increase (p < 0.001) in the frequency of MPE, indicating the sensitivity of the test system under our experimental conditions. The study was therefore considered valid. - Conclusions:
- Interpretation of results (migrated information): negative
Under our experimental conditions, the test item did not induce damage to the chromosomes or the mitotic apparatus of mice bone marrow cells after two intraperitoneal administrations, at a 24-hour interval, at the dose-levels of 500, 1000 or 2000 mg/kg/day. - Executive summary:
A preliminary toxicity test was performed to define the dose-levels to be used for the cytogenetic study.
In the main study, three groups of five male and five female mice received two intraperitoneal treatments at dose-levels of 500, 1000 or 2000 mg/kg/day, at a 24-hour interval.
One group of five males and five females received the vehicle (corn oil) under the same experimental conditions, and acted as control group.
One group of five males and five females received the positive control test item (cyclophosphamide) once by oral route at the dose-level of 50 mg/kg.
The animals of the treated and vehicle control groups were killed 24 hours after the last treatment and the animals of the positive control group were killed 24 hours after the single treatment. Bone marrow smears were then prepared.
For each animal, the number of the micronucleated polychromatic erythrocytes (MPE) was counted in 2000 polychromatic erythrocytes. The polychromatic (PE) and normochromatic (NE) erythrocyte ratio was established by scoring a total of 1000 erythrocytes (PE + NE).
The top dose-level for the cytogenetic test was selected according to the criteria specified in the international guidelines; since no severe toxic effects were observed, the top dose-level was 2000 mg/kg/day.
The two other selected dose-levels for the main test were 500 and 1000 mg/kg/day. For both males and females, the mean values of MPE in the groups treated with the test item, were equivalent to those of the vehicle control group. The PE/NE ratio was significantly lower when compared to that of the vehicle control group, in the males treated at 2000 mg/kg/day, showing that the bone marrow cells were effectively exposed to the test item.
Cyclophosphamide induced a highly significant increase in the frequency of MPE, indicating the sensitivity of the test system under our experimental conditions. The study was therefore considered valid.
Under our experimental conditions, the test item did not induce damage to the chromosomes or the mitotic apparatus of mice bone marrow cells
after two intraperitoneal administrations, at a 24-hour interval, at the dose-levels of 500, 1000 or 2000 mg/kg/day.
- Endpoint:
- in vivo mammalian germ cell study: gene mutation
- Data waiving:
- other justification
- Justification for data waiving:
- other:
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Additional information
Justification for classification or non-classification
Available data shows a negative outcome for genotoxicity based on these results, the data is conclusive but not sufficient for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.